Published in Immunochemistry on January 01, 1972
Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest (1999) 7.69
WISP genes are members of the connective tissue growth factor family that are up-regulated in wnt-1-transformed cells and aberrantly expressed in human colon tumors. Proc Natl Acad Sci U S A (1998) 3.73
Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity (2000) 3.45
Immunoglobulins cytophilic for human lymphocytes, monocytes, and neutrophils. J Clin Invest (1975) 3.39
The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. Nature (1996) 3.34
Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature (1998) 2.98
Normal embryo fibroblasts release transforming growth factors in a latent form. J Cell Physiol (1984) 2.76
Conversion of a high molecular weight latent beta-TGF from chicken embryo fibroblasts into a low molecular weight active beta-TGF under acidic conditions. Biochem Biophys Res Commun (1985) 2.75
Regulation of methionine synthesis in Salmonella typhimurium: mutants resistant to inhibition by analogues of methionine. Genetics (1968) 2.62
Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J Biol Chem (2001) 2.40
Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells. J Biol Chem (1984) 2.22
Strand-selective repair of DNA damage in the yeast GAL7 gene requires RNA polymerase II. J Biol Chem (1992) 1.94
Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia-induced apoptosis. Blood (2000) 1.90
Beta-transforming growth factor is stored in human blood platelets as a latent high molecular weight complex. Biochem Biophys Res Commun (1986) 1.90
Familial dementia caused by polymerization of mutant neuroserpin. Nature (1999) 1.88
Further study of beta-TGFs released by virally transformed and non-transformed cells. Int J Cancer (1985) 1.77
Molecular evolution of plasminogen activator inhibitor-1 functional stability. EMBO J (1995) 1.73
Reverse fibrin autography: a method to detect and partially characterize protease inhibitors after sodium dodecyl sulfate--polyacrylamide gel electrophoresis. Anal Biochem (1984) 1.59
Preferential repair of DNA damage on the transcribed strand of the human metallothionein genes requires RNA polymerase II. Mutat Res (1991) 1.58
Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J Biol Chem (2001) 1.58
Latent beta-transforming growth factor in nontransformed and Kirsten sarcoma virus-transformed normal rat kidney cells, clone 49F. Cancer Res (1984) 1.51
The thrombomodulin analog Solulin promotes reperfusion and reduces infarct volume in a thrombotic stroke model. J Thromb Haemost (2011) 1.51
Dietary fish oil and olive oil supplementation in patients with rheumatoid arthritis. Clinical and immunologic effects. Arthritis Rheum (1990) 1.50
Neuroserpin, a brain-associated inhibitor of tissue plasminogen activator is localized primarily in neurons. Implications for the regulation of motor learning and neuronal survival. J Biol Chem (1997) 1.47
Every-other-week methotrexate in patients with rheumatoid arthritis. A double-blind, placebo-controlled prospective study. Arthritis Rheum (1995) 1.44
Plasminogen activator inhibitor-1 contains a cryptic high affinity binding site for the low density lipoprotein receptor-related protein. J Biol Chem (1998) 1.42
Inhibition of angiogenesis in vivo by plasminogen activator inhibitor-1. J Biol Chem (2000) 1.40
The active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesion. Structure (1999) 1.40
Cell cycle progression of glutathione-depleted human peripheral blood mononuclear cells is inhibited at S phase. J Immunol (1989) 1.38
Cytophilic properties of IgA to human neutrophils. Adv Exp Med Biol (1974) 1.38
The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. Cancer Res (1994) 1.36
Mycobacterium avium infections in man. Am J Med (1973) 1.25
Characterization of an IgE receptor isolated from cultured B-type lymphoblastoid cells. J Immunol (1978) 1.23
Activated T cells enhance nitric oxide production by murine splenic macrophages through gp39 and LFA-1. Eur J Immunol (1995) 1.23
Effect of pharmacologic plasminogen activator inhibitor-1 inhibition on cell motility and tumor angiogenesis. J Thromb Haemost (2006) 1.21
Lead differentially modifies cytokine production in vitro and in vivo. Toxicol Appl Pharmacol (1996) 1.17
Familial encephalopathy with neuroserpin inclusion bodies. Am J Pathol (1999) 1.16
A fluorescent probe study of plasminogen activator inhibitor-1. Evidence for reactive center loop insertion and its role in the inhibitory mechanism. J Biol Chem (1995) 1.16
Regulation of the methionine-specific aspartokinase and homoserine dehydrogenase of Salmonella typhimurium. J Gen Microbiol (1968) 1.13
Neuroserpin mutation S52R causes neuroserpin accumulation in neurons and is associated with progressive myoclonus epilepsy. J Neuropathol Exp Neurol (2000) 1.08
2,4-Dinitrophenyl receptors on mouse thymus and spleen cells. J Exp Med (1973) 1.07
Talc granulomas of the skin. JAMA (1966) 1.07
Stimulation of murine lymphocyte responses by cations. Cell Immunol (1986) 1.06
Effects of high-dose fish oil on rheumatoid arthritis after stopping nonsteroidal antiinflammatory drugs. Clinical and immune correlates. Arthritis Rheum (1995) 1.06
Acidic cellular environments: activation of latent TGF-beta and sensitization of cellular responses to TGF-beta and EGF. Int J Cancer (1989) 1.05
Saturation mutagenesis of the plasminogen activator inhibitor-1 reactive center. J Biol Chem (1992) 1.05
Susceptibility of C5-deficient mice to listeriosis: modulation by Concanavalin A. Cell Immunol (1978) 1.04
Heterogeneous nuclear ribonucleoprotein E1B-AP5 is methylated in its Arg-Gly-Gly (RGG) box and interacts with human arginine methyltransferase HRMT1L1. Biochem J (2001) 1.04
Inactivation of plasminogen activator inhibitor by oxidants. Biochemistry (1986) 1.04
Identification and activation of latent transforming growth factor beta. Methods Enzymol (1991) 1.04
Endothelial cells inhibit flow-induced smooth muscle cell migration: role of plasminogen activator inhibitor-1. Circulation (2001) 1.04
Isolation of a heat-stable crystalline protein from psoriatic scales. Biochemistry (1965) 1.03
Treatment of male hypogonadism with testosterone enanthate. J Clin Endocrinol Metab (1980) 1.03
Role of the catalytic serine in the interactions of serine proteinases with protein inhibitors of the serpin family. Contribution of a covalent interaction to the binding energy of serpin-proteinase complexes. J Biol Chem (1995) 1.02
Regulation of the methionine feedback-sensitive enzyme in mutants of Salmonella typhimurium. J Bacteriol (1972) 1.01
Alteration of transforming growth factor-beta1 response involves down-regulation of Smad3 signaling in myofibroblasts from skin fibrosis. Am J Pathol (2001) 0.99
The serpin-proteinase complex revealed. Nat Struct Biol (1997) 0.96
Measurement of macrophage adherence and spreading with weak electric fields. J Immunol Methods (1990) 0.94
Level of methionyl-tRNA synthetase in merodiploids of Escherichia coli K12. Eur J Biochem (1970) 0.94
In vivo the environmental pollutants lead and mercury induce oligoclonal T cell responses skewed toward type-2 reactivities. Cell Immunol (1997) 0.94
Transforming growth factor-beta1 enhances the lethal effects of DNA-damaging agents in a human lung-cancer cell line. Int J Cancer (1997) 0.94
A histological comparison of adenomatous and hyperplastic parathyroid glands. J Clin Pathol (1978) 0.93
Serpin conformational change in ovalbumin. Enhanced reactive center loop insertion through hinge region mutations. Biochemistry (1997) 0.93
Cells transformed by Rous sarcoma virus release transforming growth factors. J Cell Physiol (1982) 0.93
Metal-induced modulation of nitric oxide production in vitro by murine macrophages: lead, nickel, and cobalt utilize different mechanisms. Toxicol Appl Pharmacol (1996) 0.92
Plasminogen activator inhibitor-1 and vitronectin expression level and stoichiometry regulate vascular smooth muscle cell migration through physiological collagen matrices. J Thromb Haemost (2010) 0.92
New Zealand mixed mice: a genetic systemic lupus erythematosus model for assessing environmental effects. Environ Health Perspect (1999) 0.92
Differential in vitro effects of physiological and atmospheric oxygen tension on normal human peripheral blood mononuclear cell proliferation, cytokine and immunoglobulin production. Int J Immunopharmacol (1996) 0.91
Lead potentiates cytokine- and glutamate-mediated increases in permeability of the blood-brain barrier. Neurotoxicology (1998) 0.91
Differential effects of concanavalin A and phytohemagglutinin on murine immunity. Suppression and enhancement of humoral immunity. Cell Immunol (1977) 0.91
Modulation of T-cell functions. I. Effect of 2-mercaptoethanol and macrophages on T-cell proliferation. Cell Immunol (1980) 0.89
Noninhibitory PAI-1 enhances plasmin-mediated matrix degradation both in vitro and in experimental nephritis. Kidney Int (2006) 0.89
Rosuvastatin reduced deep vein thrombosis in ApoE gene deleted mice with hyperlipidemia through non-lipid lowering effects. Thromb Res (2012) 0.89
Sarcoidosis associated with Crohn's disease of ileum, mouth and oesophagus. J R Soc Med (1983) 0.89
Mechanisms for the cytotoxicity of cysteamine. Toxicol Sci (2001) 0.89
Characterization and comparative evaluation of a structurally unique PAI-1 inhibitor exhibiting oral in-vivo efficacy. J Thromb Haemost (2004) 0.89
Methylation of protein by calf spleen methylase. A new protein methylation reaction. J Biol Chem (1969) 0.89
Heavy metal modulation of lymphocyte activities. 1. In vitro effects of heavy metals on primary humoral immune responses. Toxicol Appl Pharmacol (1981) 0.89
Peptide-mediated inactivation of recombinant and platelet plasminogen activator inhibitor-1 in vitro. J Clin Invest (1995) 0.88
The efficiency of maternal transfer of lead and its influence on plasma IgE and splenic cellularity of mice. Toxicol Sci (2000) 0.88
Kinetics of inactivation of alpha-thrombin by plasminogen activator inhibitor-1. Comparison of the effects of native and urea-treated forms of vitronectin. J Biol Chem (1993) 0.88
The oxidative inactivation of plasminogen activator inhibitor type 1 results from a conformational change in the molecule and does not require the involvement of the P1' methionine. J Biol Chem (1991) 0.87
A Bence Jones cryoglobulin: chemical, physical and immunological properties. Clin Exp Immunol (1967) 0.87
Suppression of methionyl transfer RNA synthetase mutants of Salmonella typhimurium by methionine regulatory mutations. J Gen Microbiol (1970) 0.87
Differences in the occurrence of hypertension among (NZB X NZW)F1, MRL-lpr, and BXSB mice with lupus nephritis. Am J Pathol (1984) 0.87
Reduced glutathione is highly expressed in white matter and neurons in the unperturbed mouse brain--implications for oxidative stress associated with neurodegeneration. Brain Res (2009) 0.87
Identification of tissue-type plasminogen activator-specific plasminogen activator inhibitor-1 mutants. Evidence that second sites of interaction contribute to target specificity. J Biol Chem (1995) 0.87
Growth stimulation of murine fibroblasts by TGF-beta1 depends on the expression of a functional p53 protein. Oncogene (1999) 0.87
Determination of glutathione in lymphocytes and possible association of redox state and proliferative capacity of lymphocytes. Biochem J (1981) 0.87
The heavy metal lead exhibits B cell-stimulatory factor activity by enhancing B cell Ia expression and differentiation. J Immunol (1990) 0.87
Problems and coping strategies of individuals with traumatic brain injury and their spouses. Arch Phys Med Rehabil (1991) 0.87
Differential effects of lead and cAMP on development and activities of Th1- and Th2-lymphocytes. Toxicol Sci (1998) 0.87
Fluorometric quantitation of cellular and nonprotein thiols. Anal Biochem (1986) 0.87
Beyond fibrinolysis: the role of plasminogen activator inhibitor-1 and vitronectin in vascular wound healing. Trends Cardiovasc Med (1998) 0.86
Effect of lead on macrophage function. J Leukoc Biol (1988) 0.86
Plasminogen activator inhibitor-1 and vitronectin promote the cellular clearance of thrombin by low density lipoprotein receptor-related proteins 1 and 2. J Biol Chem (1996) 0.86
Lead, a major environmental pollutant, is immunomodulatory by its differential effects on CD4+ T cells subsets. Toxicol Appl Pharmacol (1991) 0.86
Evidence for a methylated protein intermediate in pituitary methanol formation. Biochem Biophys Res Commun (1973) 0.86
Immunomodulation by metals. Fundam Appl Toxicol (1994) 0.86